© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dipyridamole as a drug emerged in the 1950s when researchers started exploring ways to support vascular health and address clotting disorders. Back then, industrial production focused mostly on finished active pharmaceutical ingredients, but the spotlight later shined on intermediates as regulatory, cost, and quality pressures increased. Chemists learned that careful design and mastery over intermediate stages, including those for dipyridamole, often made the difference between a batch that worked in the clinic and one that failed quality control. Over decades of clinical use, refinements in the manufacturing steps and handling of dipyridamole intermediates not only improved yields, they also brought consistency in how quickly and reliably the medicine could reach patients.
Thanks to advances in organic chemistry, dipyridamole intermediates have shed many of the headaches of batch variability and contamination that plagued early manufacturers. Companies now usually target highly specific chemical forms that feed directly into the synthesis of dipyridamole. Because this compound aims for cardiovascular applications, there’s pressure to use only intermediates meeting rigorous purity standards, often measured down to parts per million for certain impurities. Chemical suppliers have responded by modernizing their processes, with batch records, cross-contamination controls, and traceability from raw material to final product.
Chemical synthesis routes for dipyridamole produced intermediates that range from pale yellow solids to colorless oils. Under standard laboratory conditions, many show melting or boiling points in mid-range, which means that even small temperature changes can change their handling requirements. Some are sensitive to hydrolysis, so exposure to humidity in the plant or warehouse can set off degradation, which means storage in tightly sealed containers often becomes non-negotiable. Many intermediates dissolve well in polar organic solvents, which makes them easy to purify by crystallization or extraction. Density and vapor pressure figures often line up with values seen for similar nitrogen-containing aromatic compounds, pointing to well-understood risks and storage requirements.
Any serious supplier for dipyridamole intermediates knows that the label tells a key part of the quality story. Every drum or flask must show batch number, net and gross weights, production date, and storage instructions. Clear hazard statements and pictograms flag the potential health and environmental risks to those who handle the material. Customers in regulated markets expect not just typical chemical analysis but full compliance documentation—heavy metals, residual solvents, and even bioburden reports. Over time, I’ve seen that precision in technical sheets and honest dialogue between chemist and supplier avoids downtime, product loss, and compliance headaches.
The journey from basic starting materials to dipyridamole intermediate often follows a multi-step synthetic pathway. Aromatic nitro compounds react with hydrazines, amidines, or appropriate alkyl halides to lay down the core skeleton. Each step introduces or protects functional groups in ways that control the product’s structure. Common steps include condensation, cyclization, and selective reduction. In several labs I’ve visited, scale-up means continuous monitoring—temperature, pH, and stirring—because even a small deviation can cascade into a ruined batch. To gain even minor productivity improvements, technicians have developed phase-transfer catalysts, improved solvent recovery practices, or swapped out expensive reagents for more robust alternatives without compromising safety or purity.
Manipulation of dipyridamole intermediates often calls for careful control of redox and coupling steps. Nucleophilic substitution lays down amine groups that become key points of later derivatization. Selective hydrogenation or oxidation steps require catalysts tuned to avoid over-reduction or side reactions. Downstream, the ability to tweak solubility, lipophilicity, or electronic properties through minor modifications leads to improved yields during purification. Some groups run screens on several routes at once before doubling down on the pathway that balances cost, regulatory compliance, and waste minimization. The confidence to select the right chemical tweak comes with years of patient lab work and willingness to iterate after each failed run.
Dipyridamole intermediates don’t carry the name recognition of the finished drug. Synonyms and code numbers differ among suppliers and patents, often causing confusion for new procurement staff and researchers. A single intermediate might turn up as “4,4’-diaminodipyridyl,” a research code, or an abbreviated three-letter shortcut in lab books. Large-volume buyers have learned to always request detailed CAS numbers and IUPAC names to avoid mix-ups—especially with such similarity between intermediates and structural analogues. Label clarity and stable naming conventions make life easier for everyone from procurement to the quality control lab.
Chemical synthesis of dipyridamole intermediates runs best under strict safety guidelines. Common issues include inhalation hazards and skin contact risks, thanks to the aromatic amine content and the potential for volatile side-products. Industrial health and safety rules push every handler to use gloves, goggles, and sometimes full respirators. Ventilation and chemical waste traps form the backbone of every responsible plant’s design. Emergency procedures—spills, exposures, equipment failure—are drilled into every shift. The importance of keeping fire-fighting gear, first-aid kits, and wash stations within sight has been proven time and time again. Operators who treat every batch like their own safety depends on it rarely regret the extra effort.
Although the spotlight shines on dipyridamole’s antiplatelet properties in cardiovascular medicine, its intermediates support a broader reach. Custom chemists run off batches for analog development, tool compounds in basic research, and comparative toxicology trials. Formulation groups sometimes leverage certain intermediates for prodrug design, exploring routes that bypass some of dipyridamole’s absorption barriers. Proper handling and traceability keep new ideas flowing from bench to clinical trial. In my experience, tightening collaboration between process development groups and application scientists often means faster pivoting in the face of shifting market or regulatory requirements.
Every year, research teams worldwide push dipyridamole synthesis and its intermediates into new territory. Cleaner, more selective routes open the door to less costly active pharmaceutical ingredient manufacture. Many scientists now focus on environmental impact and green chemistry, swapping out toxic solvents for safer alternatives and compressing multi-step syntheses into shorter runs. There’s momentum behind continuous flow processing, which can improve yields and make scale-up more predictable. Universities play a big role here, feeding clever synthetic shortcuts and new understanding of reaction mechanisms into the commercial pipeline. Jumping in person from a research bench to a manufacturing plant reminds me how critical ongoing funding and knowledge sharing really are—it’s one thing to invent a reaction, another to make it safe and reliable on a metric-ton scale.
The need to understand toxicity in intermediates runs parallel to that for finished drugs. Aromatic amines and related byproducts, sometimes present in trace amounts, can be mutagenic or allergenic. Rigorous testing—animal models, in vitro assays, environmental fate assessments—sits squarely in the path before any intermediate gets a green light for pharmaceutical use. Over the years, some suppliers have faced product recalls after underestimating trace impurities. Best practice means running regular screens for unknowns, keeping workers trained on exposure limits, and refining purification steps as analytical technology improves. Researchers in toxicology stress constant vigilance—either upstream in development or downstream after a signal is picked up in the supply chain.
Advances in automation, process analytics, and greener chemistry promise to reshape how dipyridamole intermediates get made and tracked. As regulatory bodies in major markets tighten standards for impurity profiles and traceability, companies that invest early in high-quality digital batch records and real-time analytics position themselves for success. Rapid shifts in health needs, such as the push for antithrombotic drugs after global events, force technical teams to stay nimble. With experience comes the understanding that process improvements and environmental best practices matter both for near-term cost savings and the long-term sustainability of the global chemical supply chain. The next few years will likely bring deeper partnerships between academics, industry engineers, and regulatory scientists, setting a new bar for safety, consistency, and innovation in the world of dipyridamole intermediates.
Walk into a pharmacy, check the shelves, and you’ll see medicines that save lives and help manage chronic health conditions. It’s easy to forget—the real action starts much earlier, long before those tablets reach a bottle. Dipyridamole intermediate plays a role in this journey. This chemical, used in medicine manufacturing, is a link in the chain for producing dipyridamole, which helps patients dealing with heart or circulation problems.
Dipyridamole finds a spot on many cardiologists' treatment lists, often handed out with other drugs. It helps keep platelets from clumping together, lowering the risk of clots that could lead to strokes or other circulation problems. For years, doctors have leaned on it, especially for patients with prosthetic heart valves or after minor strokes. The intermediate shows up much earlier, during the lab stages, as manufacturers build the final medicine molecule.
Making medications is rarely simple. The active ingredient—what actually changes things inside our bodies—often starts life as a string of chemical compounds. Each one gets layered and transformed in carefully controlled steps. That’s where intermediates step in. In my experience growing up in a family of pharmacists, I saw how these chemical steps matter. If an intermediate like the one used for dipyridamole isn’t pure or reliable, the final medicine can’t be trusted.
Regulations keep manufacturers in check. Health authorities ask for proof at every stage, including the intermediate phase. These checks matter—poor-quality intermediates in medicine production have, in rare cases, led to serious recalls. Real-life mistakes have cost companies millions and put patient safety at risk.
Current events show medicine makers hitting bumps in the road. Supply chains get stretched—they rely on global partners for everything, including dipyridamole intermediates. A shipment stuck at a port, or a problem in the lab, may halt production. Just last year, the world saw several cardiovascular drugs in short supply, sending ripples through hospitals. Reliable sources and strong relationships with trusted chemical producers help stop these disruptions.
Everyone deserves medicine that does what it promises. That starts with every ingredient. History shows what happens when shortcuts meet science. In the late 2000s, contamination in an intermediate for another heart drug caused a cascade of harm, a story that lingers in the minds of anyone in pharmaceutical circles. Strong rules exist for a reason. Drug companies run strict labs and keep careful records because the smallest flaw in an intermediate can have outsized effects.
Modern advances help. New sensors, better purification tools, and smarter tracking tech catch problems before they leave the lab. Two years ago, I helped a small company digitize its quality checks. Tiny errors popped up on-screen in real-time—no paperwork shuffle, no missed warning signs. The industry keeps moving, always looking for ways to catch errors before they touch a single patient.
Behind every safe tablet is a long line of careful choices. The story of dipyridamole intermediate tells us a lot about trust, safety, and the everyday work that keeps life-saving medicine real.
Anyone involved with pharmaceuticals knows that the journey from raw materials to final medicine isn't smooth sailing. Take Dipyridamole Intermediate, for instance. This compound might not seem glamorous, but mistakes during storage can turn years of hard work into a pile of wasted resources. At risk is not just money, but public health. So while labels and safety data sheets matter, paying attention on the ground makes the difference in real-world settings.
Dipyridamole Intermediate sits several steps away from the final drug, but its quality shapes what comes next. Storage isn't just about finding any free corner in a warehouse. This substance responds to heat, moisture, and light. Sitting by a sunny window can break down sensitive bonds, making the next batch unreliable. Factories with leaky roofs or out-of-whack air conditioning will see purity drop over time, breaking compliance and forcing expensive retesting or recalls.
I've watched warehouses in humid climates experience the domino effect: untouched intermediates slowly degrade, humidity climbs, and suddenly every downstream process slows because something just isn't right with the starting material. Investing in a good storage system, with temperature and humidity under control, saves a lot more hassle than clever paperwork ever could.
Real safety starts with clear company guidelines based firmly on science, not shortcuts. Dipyridamole Intermediate thrives in cool, dry conditions. Temperatures between 2°C and 8°C work well for long-term storage, though the specifics come from the actual certificate of analysis or manufacturer’s technical documents. An insulated, separate area helps avoid temperature swings caused by frequent door openings. Even seemingly small variations in temperature, seen in old fridges or busy stockrooms, create inconsistencies over months.
Desiccant packs help keep excess moisture in check, but only if someone checks them and replaces them as needed. I've seen sites where these packs were just tossed in bins and forgotten for years. Properly sealed, airtight drums or specialized chemical containers cut down the risks brought in by leaky packaging or daily handling. Labels need to be robust — ink that won’t fade, labels that won’t peel off. Facilities should avoid strong sunlight and direct heat sources, not just because of potential chemical breakdown, but because labeling and tamper seals degrade too.
No one wants to open a container and catch a strange whiff signaling chemical change, or see unexpected discoloration — both red flags. Routine checks matter. They aren't busywork, but the basic duty of care for everyone downstream. Gloves, goggles, and well-ventilated areas aren't for show. Even intermediates that seem harmless deserve respect to limit cross-contamination and chemical exposure.
Training matters, since lapses come from staff who haven’t seen trouble yet. Involve everyone with regular updates and refreshers. Poor storage isn’t just a technical glitch; at worst, it seeps into every tablet, capsule, or injectable product using that intermediate.
Paper logs still dot many warehouses, but digital systems now offer better traceability and instant alerts for temperature or humidity swings. Logs with batch numbers, location, and dates cut down the odds of mixing up supplies or keeping spoiled chemicals in rotation. Auditable records meet regulators’ expectations and keep doors open for export and insurance coverage.
Quality storage for Dipyridamole Intermediate builds a stronger chain of trust, stretching from suppliers to patients. Pharmacies, hospitals, and everyday people rely on safe, consistent medicine. Maintaining strict, practical storage routines avoids risk and protects all the effort poured into developing treatments that truly help communities.
A lot of researchers and pharmaceutical professionals ask about Dipyridamole intermediates because they form the backbone of an important class of antiplatelet drugs. The chemical formula for one key intermediate, 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine, runs as C24H38N8O4. This formula often comes up in literature when discussing the practical process of making Dipyridamole.
Understanding what goes into the heart of a drug like Dipyridamole gives a clear picture of why quality control checks focus so closely on the intermediate. Chemistry isn’t just about mixing things together and hoping for the best. In my time spent collaborating with pharmaceutical partners, missing even a single atom or adding an unwanted group can ruin a batch. The intermediate defines both the structure and the safety of the final drug, making its formula a serious checkpoint in the process.
The journey from raw materials to a finished drug requires precision. Dipyridamole’s intermediate, with its specific blend of piperidine and diethanolamine groups attached to a pyrimidine ring, acts as more than a stepping-stone. Decisions made at this stage — temperature, solvents, even timing — influence purity and yield. Any deviation can cause dangerous impurities, which regulators won’t overlook.
I once watched a batch fail at a contract manufacturing facility. The chemist misread the intermediate’s formula, and the entire process had to stop. Waste and cost aside, the bigger risk turned out to be a loss of trust. Suppliers, regulators, and patients depend on a repeatable outcome. Knowing exactly what should be present in an intermediate keeps everyone aligned.
Transparency about what’s inside each barrel or vial matters in this industry. With Dipyridamole, the science running through C24H38N8O4 gets checked with rigorous lab methods like HPLC, NMR, and mass spectrometry. These tests match each batch against the expected intermediate, flagging errors before they reach patients. The growing focus on data integrity means labs document every single reading, so any discrepancy becomes traceable.
Better training for lab staff, clearer chemical labeling, and automation in documentation can reduce confusion about formulas. Digital records let chemists compare past runs, spot trends, and correct errors quickly. Regulatory agencies, pushing for regular audits, prompt companies to prioritize accuracy at each step. Third-party labs verify the intermediate’s structure, adding another layer of safety.
In the end, the formula for a Dipyridamole intermediate represents more than numbers and letters. It shows a chain of responsibility that stretches from chemists through to patients. Each link—lab test, production run, regulatory check—relies on getting that formula right, day after day. That’s what keeps medicine trustworthy and lives protected.
Everyone working in pharma knows how crucial a steady supply chain becomes once market demand heats up. Dipyridamole, a staple in cardiovascular therapy, relies on intermediates that rarely get attention outside chemical procurement circles. Access to these intermediates determines how soon manufacturers can push finished batches to wholesalers, hospitals, and pharmacies. Questions around bulk availability touch on something bigger: the strength and reliability of the global pharmaceutical supply chain itself.
Chemistry majors might remember their first encounter with process scale-up. Taking a lab-scale synthesis to multi-ton production often looks straightforward at first glance. Behind the scenes, managing a dipyridamole intermediate means keeping tabs on supply agreements, purity specs, and regulatory paperwork. If just one batch of intermediate arrives late or under-spec, the dominoes start to fall—tight production schedules tumble, shipments face delay, and ultimately, the availability of lifesaving medications shrinks.
Most global suppliers for dipyridamole intermediates operate out of India and China, reflecting an industry-wide lean toward cost reduction. Pharmaceutical producers in the US and EU still rely heavily on these overseas sources. This dependence brings built-in risks. COVID-19 disruptions peeled back the curtain on just how fragile global sourcing can be. One closed port or an export ban, and the downstream effects travel fast: price spikes, contract disputes, nervous buyers hedging orders.
Sourcing in bulk means more than just finding a supplier with a few metric tons to spare. Compliance with Good Manufacturing Practice (GMP) standards is non-negotiable. Regulatory agencies like the US FDA and Europe’s EMA have increased scrutiny, especially after past recalls of poorly synthesized pharmaceutical ingredients. Manufacturers chase not only scale but documented, auditable quality—from starting material through the final active compound. Lapses lead to more than lost batches; they set the stage for recalls and regulatory penalties.
From experience, building flexibility into procurement pays off. Companies shop around, not just for the best price, but for dual sources that shrink risk in uncertain times. Keeping some inventory close at hand, even if warehouse space costs extra, cushions against unforeseen blows. Contract manufacturing organizations (CMOs) have grown into an essential safety net, allowing smaller producers to scale output or manage a surprise spike in demand without scrambling for raw materials.
Direct conversations with suppliers reveal more than what any official press release shares. Relationship management plays a bigger role than most outsiders believe. Closely tracking shifts in raw material pricing, regulatory updates, and logistics setbacks can position a procurement team to act preemptively. Tech advances, like supply chain tracking through blockchain or AI-driven demand forecasting, offer hope for more transparency and reliability going forward.
Bulk availability of dipyridamole intermediates signals how prepared the pharmaceutical sector stands to weather shocks. Domestic investment in chemical manufacturing infrastructure would strengthen resilience. Ongoing training for staff and robust audit trails can guard against cloudy quality issues. The industry’s future will depend not just on chemistry know-how, but on smart, proactive supply chain management and honest, two-way supplier relationships.
Dipyridamole Intermediate sits on a shelf in many pharmaceutical facilities. I remember stepping into a lab as a student and seeing mountains of bottles with names I could barely pronounce, let alone understand their hazards. This compound has a real job – it's a building block for cardiovascular medication – but it brings plenty of risks if left unchecked.
The material comes with risks even seasoned chemists respect. Inhalation, skin contact, or accidental splashes can spark trouble fast. The chemical may cause respiratory irritation or discomfort, and long-term exposure could lead to different health concerns. A good safety data sheet makes this clear, laying out toxicological data alongside first-aid instructions. I once watched a colleague ignore a warning label; an accidental whiff sent him coughing for days.
Gloves, goggles, and lab coats aren’t suggestions— they form the real armor in chemical handling. Use nitrile gloves that stand up to harsh solvents. Goggles fit tightly around the eyes, stopping splashes before they reach delicate tissues. Never think a pair of prescription glasses counts: chemical splashes can slip right around. Protective clothing that covers the arms and legs gives extra insurance against accidental drips or drops. Keep it simple: better to sweat a bit than race to urgent care.
Fume hoods pull danger away from faces and lungs. Anyone who’s worked a long shift with organics knows how tired a dull headache can make you feel after breathing low concentrations for hours. Strong ventilation ensures vapors don’t hang in the air. Work inside enclosed spaces with negative pressure when weighing or transferring powder. Dust control strategies, like using weighing funnels and wetting agents, cut down on airborne particles.
Don’t eat or drink around chemicals— no exceptions. It’s tempting to bring a coffee to the bench, but even a drop of contaminated liquid spells trouble. Hand-washing goes beyond routine hygiene. Thorough scrubbing with soap and water keeps residues from slipping into mouths or eyes. Clothes worn in the lab should stay out of the home, washing hands before touching personal items each time you leave the workspace.
I’ve seen labs freeze when spills happen. Mixing up the order of an eyewash protocol, or fumbling with a safety shower during a crisis, makes a bad moment worse. Emergency showers and eyewash stations must be within a short sprint. Fire extinguishers and spill kits should stay stocked and easy to reach. Memorize the layout; don't hunt for lifesaving equipment under stress. Routinely practice drills, not just once a year. Confidence in response comes from repetition, not instruction manuals.
All lab workers need regular training. Real stories stick more than slideshows – hearing about someone’s mistake makes the risk real. Ask questions if a step or piece of equipment feels off. Supervisors carry responsibility for everyone under their roof; ignoring a struggling coworker breeds risk for everyone.
Accidents often trace back to gaps in systems, not individuals. Reporting near misses and reevaluating procedures can prevent real disasters. Labs that encourage speaking up and tweaking methods build a culture stronger than any policy.
| Names | |
| Preferred IUPAC name | 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine |
| Other names |
2,6-Bis(diethoxyphosphoryl)aminopyrimidin-4-one 2,6-Bis(diethoxyphosphorylamino)-4-pyrimidinol Pyrimidine, 2,6-bis(diethoxyphosphinyl)amino-4-hydroxy- |
| Pronunciation | /daɪˌpɪrɪˈdæməˌloʊ ɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 2537-30-4 |
| 3D model (JSmol) | Sorry, I cannot provide the '3D model (JSmol)' string for 'Dipyridamole Intermediate'. |
| Beilstein Reference | 1729476 |
| ChEBI | CHEBI:4653 |
| ChEMBL | CHEMBL1427 |
| ChemSpider | 21476602 |
| DrugBank | DB00932 |
| ECHA InfoCard | ECHA InfoCard: 100.041.814 |
| EC Number | 625-50-3 |
| Gmelin Reference | Gmelin Reference: 83233 |
| KEGG | CHEBI:4673 |
| MeSH | D003978 |
| PubChem CID | 155052 |
| RTECS number | DG0875000 |
| UNII | 5Y6OM5454T |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product 'Dipyridamole Intermediate' is DTXSID80936257 |
| Properties | |
| Chemical formula | C13H19N3O |
| Molar mass | 504.63 g/mol |
| Appearance | Yellow crystalline powder |
| Odor | Odorless |
| Density | 1.4 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.6 |
| Acidity (pKa) | pKa = 6.6 |
| Basicity (pKb) | 7.64 |
| Refractive index (nD) | 1.632 |
| Dipole moment | 2.4 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 313.7 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | B01AC07 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation. |
| GHS labelling | GHS07, GHS09 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Precautionary statements: If medical advice is needed, have product container or label at hand. Keep out of reach of children. Read label before use. |
| Flash point | 120°C |
| LD50 (median dose) | LD50 (median dose): Oral rat LD50 > 5000 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 40 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Dipyridamole 2,6-Dichloropyridine 4-Aminopyridine Pyridone derivatives Piperidine derivatives |
